Tetiana Taran | Academic Influence

Tetiana Taran's AcademicInfluence.com Rankings

Tetiana Taran

Mathematics

#6226

World Rank

#8663

Historical Rank

Group Theory

#574

World Rank

#676

Historical Rank

Number Theory

#560

World Rank

#691

Historical Rank

Algebra

#894

World Rank

#1168

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Tetiana Taran's Degrees

PhD Mathematics Taras Shevchenko National University of Kyiv
Masters Mathematics Taras Shevchenko National University of Kyiv
Bachelors Mathematics Taras Shevchenko National University of Kyiv

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Tetiana Taran Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Tetiana Arkhipivna Taran was a Soviet and Ukrainian computer scientist who worked in artificial intelligence, published the first Russian-language textbook in artificial intelligence, and founded the series of International Conferences on Data Science and Intelligent Analysis of Information.

(See a Problem?)

Tetiana Taran's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ESR1 ligand binding domain mutations in hormone-resistant breast cancer (2013) (908)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. (2014) (459)
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. (2014) (432)
Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013) (391)
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. (2015) (250)
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. (2008) (227)
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. (2016) (205)
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. (2016) (132)
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. (2013) (101)
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 (2014) (101)
Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial (2013) (92)
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. (2013) (85)
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (2016) (73)
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy (2013) (64)
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 (2013) (60)
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. (2013) (54)
Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2014) (46)
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. (2014) (25)
Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2: a phase III trial of everolimus for postmenopausal women with advanced breast cancer (2012) (21)
Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2− advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy (2013) (20)
Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial (2013) (16)
Abstract S6-01: Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1 (2015) (14)
Abstract 4564: Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial. (2013) (7)
Abstract P3-15-03: Safety analysis of BOLERO-3: A phase 3 trial of daily everolimus (EVE) vs placebo (PBO), both with weekly trastuzumab (TRAS) and vinorelbine in trastuzumab-resistant, advanced breast cancer (2013) (3)
Abstract P4-13-12: Everolimus plus trastuzumab and vinorelbine for trastuzumab-resistant, taxane-pretreated, HER2+ advanced breast cancer: Overall survival results from BOLERO-3 (2016) (3)
PO59 EFFICACY AND SAFETY OF EVEROLIMUS PLUS EXEMESTANE COMBINATION THERAPY VERSUS MONOTHERAPY WITH EVEROLIMUS OR CAPECITABINE IN HR+, HER2− BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-6 (2013) (2)
Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer : BOLERO-6 (2013) (2)
Abstract P2-16-17: Characterization of response to everolimus (EVE) in BOLERO-2: A phase 3 trial of EVE plus exemestane (EXE) in postmenopausal women with HR+, HER2- advanced breast cancer (2013) (2)
Safety analysis of BOLERO-3 : a phase III trial of daily Everolimus vs placebo, both with weekly Trastuzumab and Vinorelbine in Trastuzumab-resistant, advanced breast cancer (2013) (1)
Abstract P4-12-19: BOLERO-3: Everolimus plus trastuzumab and vinorelbine in Asian patients with HER2-positive metastatic breast cancer (2013) (1)
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results From BOLERO-2 (2015) (1)
BOLERO-3 : Quality-of-life maintained in patients with HER-2 positive metastatic breast cancer treated with Everolimus plus Trastuzumab plus Vinorelbine (2013) (0)
Abstract P4-12-18: BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine (2013) (0)
BOLERO-3 : Everolimus plus Trastuzumab and Vinorelbine in asian patients with HER2-positive metastatic breast cancer (2013) (0)

This paper list is powered by the following services:

Other Resources About Tetiana Taran

en.wikipedia.org

What Schools Are Affiliated With Tetiana Taran?

Tetiana Taran is affiliated with the following schools: